Gino Santini

Gino has over a decade of board leadership and governance expertise in both public and private global corporations. He has served as an advisor and board director to European and US venture capital, pharmaceutical, and biotechnology companies since 2011, when he stepped down from executive responsibility at Eli Lilly & Company.

During his director tenure across more than ten boards, Gino has honed his governance experience as chairman, lead independent director, and in multiple committee chair roles. He has played a leading role in several M&A transactions and has significant expertise in advising on commercial partnerships. Gino currently serves as a lead independent director for Collegium Pharmaceuticals (NASDAQ: COLL) and on several private company boards.

Gino left Eli Lilly & Company as Senior Vice President of Corporate Strategy and Business Development in 2011, after a successful 27-year career. In this capacity, he was responsible for overseeing the acquisitions of Imclone (2009), Icos (2008), and several other pipeline projects. He was a member of the Executive Committee from 2004 until his departure from the company.

Gino holds a degree in Mechanical Engineering from the University of Bologna and a Master of Business Administration from the Simon School of Business, University of Rochester.